Moderna says Covid-19 vaccine shields against British, South African strains 2 minutes read
New York, Jan 25 (efe-epa).- American pharmaceutical company Moderna said Monday that its Covid-19 vaccine neutralizes the British and South African variants of the virus that causes that potentially fatal respiratory illness.
Results from in vitro neutralization studies showed broad effectiveness of the two-dose Moderna vaccine, which has been approved for emergency use in the United States, the European Union, the United Kingdom and elsewhere.
“Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers (antibody concentration in the blood) against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively,” the company said in a press release.
Does Getting the Covid-19 Vaccine Stop You Spreading It? Scientists Don t Know Yet morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
A Guide to Moderna’s COVID-19 Vaccine
This article is available in both English and Español
English
Español
Moderna’s mRNA vaccine is the second COVID-19 vaccine authorized for use in the U.S. Here, we give a rundown of basic facts about the vaccine and an overview of how it works.
Quick Summary
Dose number: 2 doses, 28 days apart
Efficacy: 94.1% efficacy in preventing symptomatic COVID-19 in adults two weeks or more after receipt of the second dose.
Safety: No serious safety concerns reported. The shots, however, commonly elicit reactions in people that can include injection site pain, fatigue, headache, muscle or joint pain, and chills.